Evidence map›Paper›PMID 34949180›Full record

ArticleJournal of nanobiotechnology2021

A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.

Xueqin Wang, Tiandi Xiong, Miao Cui, Na Li, Qin Li, Li Zhu, Shaofeng Duan, Yunlong Wang, Yuqi Guo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Nanoparticle-Based Combination Therapy for Ovarian Cancer.International journal of nanomedicine · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Xueqin WangHenan Provincial People's Hospital, Zhengzhou, 450003, China.ORCID http://orcid.org/0000-0001-8744-850X
Tiandi XiongCollege of Bioengineering, Henan University of Technology, Zhengzhou, 450001, China.
Miao CuiCollege of Bioengineering, Henan University of Technology, Zhengzhou, 450001, China.
Na LiHenan Provincial People's Hospital, Zhengzhou, 450003, China.
Qin LiHenan Provincial People's Hospital, Zhengzhou, 450003, China.
Li ZhuHenan Provincial People's Hospital, Zhengzhou, 450003, China.
Shaofeng DuanInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, 475004, China. sduan@henu.edu.cn.
Yunlong WangHenan Bioengineering Research Center, Zhengzhou, 450046, China. biowyl@126.com.
Yuqi GuoHenan Provincial People's Hospital, Zhengzhou, 450003, China. yuqi-guo@163.com.
Zhengzhou University · CNHenan University of Technology · CNHenan Bioengineering Technology Research Center · CNHenan University · CN

Funding

Basic Research Project of Key Scientific Research Projects in Henan Province 20zx011China Postdoctoral Science Foundation 2019M652541Henan Province medical science and technology research project jointly built by the Ministry and province SB201901073Innovation Scientists and Technicians Troop Construction Projects of Henan Province 192101510001National Natural Science Foundation of China 815 725 74Young Core Instructor Program in Higher Education Institution of Henan province 2018 GGJS 067
6 · The paper itself

Abstract

backgroundMultidrug resistance (MDR) is the main challenge of successful chemotherapy for ovarian cancer patients, with 50% to 75% of ovarian cancer patients eventually relapsed due to it. One of the effective strategies for treating MDR and improving therapeutic efficiency of ovarian cancer is to use nanotechnology-based targeted drug delivery systems. In this study, a novel nano targeted co-delivery system modified by hyaluronic acid (HA) was developed by using gold nanorods coated with functionalized mesoporous silica nanoparticles (HA-PTX/let-7a-GNR@MSN) for combined delivery of hydrophobic chemotherapy drug Paclitaxel (PTX) and lethal-7a (let-7a), a microRNA (miR), to overcome MDR in ovarian cancer. Furthermore, we also analyzed the molecular mechanism of this nanotherapeutic system in the treatment of ovarian cancer.

resultsHA-modified nanocomplexes can specifically bind to the CD44 receptor, which is highly expressed in SKOV3/SKOV3

conclusionsTo sum up, these data provide a model for overcoming PTX resistance in ovarian cancer.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicApoptosisATP Binding Cassette Transporter, Subfamily B, Member 1Cell Line, TumorDrug Resistance, NeoplasmFemaleGoldHumansMiceMice, NudeMicroRNAsNanoparticlesNanostructuresNanotubesOvarian NeoplasmsAntineoplastic Agents, PhytogenicATP Binding Cassette Transporter, Subfamily B, Member 1GoldMicroRNAsMTOR protein, humanPaclitaxelSilicon DioxideTOR Serine-Threonine KinasesCo-delivery nanosystemMultidrug resistanceOvarian cancerPTX, miR let-7a

Identifiers

PMID34949180
PMCPMC8697442
OpenAlexW4200114867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.